Glycopeptide antibiotics: back to the future

Butler, Mark S., Hansford, Karl A., Blaskovich, Mark A. T., Halai, Reena and Cooper, Matthew A. (2014) Glycopeptide antibiotics: back to the future. Journal of Antibiotics, 67 9: 631-644. doi:10.1038/ja.2014.111

Author Butler, Mark S.
Hansford, Karl A.
Blaskovich, Mark A. T.
Halai, Reena
Cooper, Matthew A.
Title Glycopeptide antibiotics: back to the future
Journal name Journal of Antibiotics   Check publisher's open access policy
ISSN 0021-8820
Publication date 2014-09
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/ja.2014.111
Open Access Status
Volume 67
Issue 9
Start page 631
End page 644
Total pages 14
Place of publication London, United Kingdom
Publisher Nature Publishing
Collection year 2015
Language eng
Abstract Glycopeptide antibiotics have been a key weapon in the fight against bacterial infections for over half a century, with the progenitors, vancomycin (1) and teicoplanin (2), still used extensively. The increased occurrence of resistance and the effectiveness of these ‘last resort’ treatments for Gram-positive infections has led to the discovery and clinical development of second generation, semisynthetic lipoglycopeptide derivatives such as telavancin (3), dalbavancin (4) and oritavancin (5), which all possess broader spectra of activity and improved pharmacokinetic properties. Two of these new antibiotics, telavancin (3) and dalbavancin (4), were approved in the past 5 years and the third, oritavancin (5), is awaiting regulatory approval. In this review, the discovery, development and associated resistance of vancomycin (1) and teicoplanin (2), and semi-synthetic glycopeptides, telavancin (3), dalbavancin (4) and oritavancin (5), are detailed. The clinical implications of glycopeptide resistance, especially vancomycin (1), as well as the future prospects for current glycopeptide drugs and the development of new glycopeptides are discussed.
Keyword Resistant Staphylococcus-Aureus
Cell-Wall Synthesis
Reduced Vancomycin Susceptibility
Infectious-Diseases Society
Community-Associated Mrsa
Hydrophobic Side-Chains
Critically-Ill Patients
In-Vitro Activity
Antibacterial Activity
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 16 Nov 2014, 00:45:19 EST by System User on behalf of Institute for Molecular Bioscience